|
2.6 ETIOLOGIE - ENVIRONNEMENT
| |
|
|
3.1 PRÉVENTION - TABAC
| |
|
|
4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...
| |
|
|
4.12 BIOPSIES LIQUIDES
| |
|
|
|
5. TRAITEMENTS
| |
|
|
|
5.10 TRAITEMENTS - ESSAIS
| |
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
| |
|
|
|
|
5.2 PHARMA
| |
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
| |
|
Can Roche’s little tech startup help the FDA change clinical trials? [STAT]
| |
|
| |
|
Zach Weinberg, 32, Flatiron’s co-founder, president, and chief operating officer, believes in his tech in a big way. During an interview, he promised Flatiron will soon publish results showing it is possible to achieve one of the major goals of the field: using data collected from health records to mimic a control group.
| |
| | |
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
| |
|
|
5.4 TRAITEMENTS - ECONOMIE
| |
|
|
5.6 ESMO
| |
|
|
|
Rare Cancers a Growing Focus of Early-stage Clinical Trials [ESMO]
| |
|
| |
|
Sato and his colleagues pooled results from 866 oncology phase 1 trials conducted worldwide for their analysis. These trials, published between 1991 and 2015, involved more than 29,000 patients enrolled to test novel medicines in the first stage of clinical testing.
| |
| | |
|
|
6. LUTTE CONTRE LES CANCERS
| |
|
Cancer services: how much is enough? [Cancer World]
| |
|
| |
|
In setting the Agenda of sustainable development goals for the near future, the United Nations decided to aim at “reducing premature deaths due to incommunicable diseases by one third by the year 2030”. The exact path to reach that ambitious target is far from clear, but the World Health Organisation (WHO) and the European Society of Medical Oncology (ESMO) are currently joining efforts to blaze a trail for cancer.
| |
| | |
|
|
6.10.1 POLITIQUES (USA)
| |
|
|
6.4 MÉDICO-ÉCO
| |
|